151 related articles for article (PubMed ID: 31784614)
21. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
22. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
Roylance R; Endesfelder D; Gorman P; Burrell RA; Sander J; Tomlinson I; Hanby AM; Speirs V; Richardson AL; Birkbak NJ; Eklund AC; Downward J; Kschischo M; Szallasi Z; Swanton C
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2183-94. PubMed ID: 21784954
[TBL] [Abstract][Full Text] [Related]
23. DNA copy number aberrations associated with aneuploidy and chromosomal instability in breast cancers.
Kawauchi S; Furuya T; Ikemoto K; Nakao M; Yamamoto S; Oka M; Sasaki K
Oncol Rep; 2010 Oct; 24(4):875-83. PubMed ID: 20811667
[TBL] [Abstract][Full Text] [Related]
24. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
[TBL] [Abstract][Full Text] [Related]
25. The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA.
Voutsadakis IA
Cancer Invest; 2021 Jan; 39(1):25-38. PubMed ID: 33306412
[TBL] [Abstract][Full Text] [Related]
26. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
Viale G
J Pathol; 2009 Sep; 219(1):1-2. PubMed ID: 19670216
[TBL] [Abstract][Full Text] [Related]
27. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
28. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
[TBL] [Abstract][Full Text] [Related]
29. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
[TBL] [Abstract][Full Text] [Related]
30. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome].
Zhang S; Wang Y; Guo ZM; Zhang H; Xu L; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):686-90. PubMed ID: 25331387
[TBL] [Abstract][Full Text] [Related]
32. Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.
Slee RB; Steiner CM; Herbert BS; Vance GH; Hickey RJ; Schwarz T; Christan S; Radovich M; Schneider BP; Schindelhauer D; Grimes BR
Oncogene; 2012 Jul; 31(27):3244-53. PubMed ID: 22081068
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
[TBL] [Abstract][Full Text] [Related]
34. Isolated CEP17 Copy Number Gain in Invasive Breast Cancer Results in a "Reverse" Amplification Status.
Van Bockstal MR; Dubois D; Talpe S; Galant C
Int J Surg Pathol; 2021 Feb; 29(1):76-77. PubMed ID: 32131665
[No Abstract] [Full Text] [Related]
35. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
36. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers.
Voutsadakis IA
Mol Diagn Ther; 2019 Dec; 23(6):707-721. PubMed ID: 31372940
[TBL] [Abstract][Full Text] [Related]
38. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
39. Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.
Zhang W; Mao JH; Zhu W; Jain AK; Liu K; Brown JB; Karpen GH
Nat Commun; 2016 Aug; 7():12619. PubMed ID: 27577169
[TBL] [Abstract][Full Text] [Related]
40. The effect of an alternative chromosome 17 probe on fluorescence
Xu Z; Xu P; Fan W; Huang B; Cheng Q; Zhang Z; Wang P; Yu M
Exp Ther Med; 2019 Sep; 18(3):2095-2103. PubMed ID: 31410164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
